Compare ALOT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALOT | ELTX |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 185.4M |
| IPO Year | 1995 | 2014 |
| Metric | ALOT | ELTX |
|---|---|---|
| Price | $28.80 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 127.0K | ★ 995.8K |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.94 | 39.29 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $150,515,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $359.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.96 | $2.66 |
| 52 Week High | $28.86 | $16.00 |
| Indicator | ALOT | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 86.63 | 36.06 |
| Support Level | $14.35 | $2.72 |
| Resistance Level | N/A | $5.38 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | -0.46 | 0.24 |
| Stochastic Oscillator | 73.61 | 18.75 |
AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Aerospace. It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.